Activation of STAT3/HIF-1α/Hes-1 axis promotes trastuzumab resistance in HER2-overexpressing breast cancer cells via down-regulation of PTEN

Biochimica et Biophysica Acta - General Subjects

Volumn 1861, Issue 8, 2017, Pages 1970-1980

  Aghazadeh, Safiyeh ^a   Yazdanparast, Razieh ^a  

^a UNIVERSITY OF TEHRAN   (Iran)

Author keywords

HIF 1 ; PTEN; STAT3; Trastuzumab resistance

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SMALL INTERFERING RNA; STAT3 PROTEIN; TRANSCRIPTION FACTOR HES 1; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; HES1 PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; ATTENUATION; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL VIABILITY; CONDITIONED MEDIUM; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION; BREAST NEOPLASMS; CHEMISTRY; DRUG RESISTANCE; FEMALE; PHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; PTEN PHOSPHOHYDROLASE; RECEPTOR, ERBB-2; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HES-1; TRASTUZUMAB;

EID: 85019668155     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2017.05.009     Document Type: Article

References (47)

1. Sørlie, T., Perou, C.M., Tibshirani, R.,et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 10869–10874.
2. Slamon, D.J., Clark, G.M., Wong, S.G.,et al., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987), 177–182.
3. Moasser, M.M., The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26 (2007), 6469–6487.
4. Badache, A., Gonçalves, A., The ErbB2 signaling network as a target for breast cancer therapy. J. Mammary Gland Biol. Neoplasia 11 (2006), 13–25.
5. Vogel, C.L., Cobleigh, M.A., Tripathy, D.,et al., Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20 (2002), 719–726.
6. Carter, P., Presta, L., Gorman, C.M.,et al., Humanization of an anti-p185 HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. U. S. A. 89 (1992), 4285–4289.
7. Le, X.F., Claret, F.X., Lammayot, A.,et al., The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J. Biol. Chem. 278 (2003), 23441–23450.
8. Nahta, R., Esteva, F.J., Herceptin: mechanisms of action and resistance. Cancer Lett. 232 (2006), 123–138.
9. Nagata, Y., Lan, K.H., Zhou, X.,et al., PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6 (2004), 117–127.
10. Korkaya, H., Kim, G.I., Davis, A.,et al., Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2 + breast cancer by expanding the cancer stem cell population. Mol. Cell 47 (2012), 570–584.
11. Sonnenblick, A., Brohée, S., Fumagalli, D.,et al., Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer. BMC Med., 3, 2015, 13 (177).
12. Clevenger, C.V., Roles of regulation of STAT family transcription factors in human breast cancer. Am. J. Pathol. 165 (2004), 1449–1460.
13. Yu, H., Lee, H., Herrmann, A.,et al., Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat. Rev. Cancer 14 (2014), 736–746.
14. Diaz, N., Minton, S., Cox, C.,et al., Activation of Stat3 in primary tumors from higher risk breast cancer patients is associated with elevated levels of activated Src and Survivin expression. Clin. Cancer Res. 12 (2006), 20–28.
15. Zhou, J., Bi, C., Janakakumara, J.V.,et al., Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood 113 (2009), 4052–4062.
16. Zhao, C., Li, H., Lin, H.J.,et al., Feedback activation of STAT3 as a cancer drug-resistance mechanism. Trends Pharmacol. Sci. 37 (2016), 47–61.
17. Siddiquee, K.Z., Turkson, J., STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res. 18 (2008), 254–267.
18. Xu, Q., Briggs, J., Park, S.,et al., Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24 (2005), 5552–5560.
19. Semenza, G.L., Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003), 721–732.
20. Semenza, G.L., Involvement of hypoxia-inducible factor 1 in human cancer. Intern. Med. 41 (2002), 79–83.
21. Yeo, E.J., Chun, Y.S., Park, J.W., New anticancer strategies targeting HIF-1. Biochem. Pharmacol. 68 (2004), 1061–1069.
22. Klos, K.S., Wyszomierski, S.L., Sun, M.,et al., ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res. 66 (2006), 2028–2037.
23. Laughner, E., Taghavi, P., Chiles, K.,et al., HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 21 (2001), 3995–4004.
24. Pawlus, M.R., Wang, L., Hu, C.J., STAT3 and HIF1α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells. Oncogene 33 (2014), 1670–1679.
25. Qiang, L., Wu, T., Zhang, H.W.,et al., HIF-1α is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway. Cell Death Differ. 19 (2012), 284–294.
26. Palomero, T., Sulis, M.L., Cortina, M.,et al., Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat. Med. 13 (2007), 1203–1210.
27. Miller, T.W., Rexer, B.N., Garrett, J.T.,et al., Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res., 13, 2011, 224.
28. Salmena, L., Carracedo, A., Pandolfi, P.P., Tenets of PTEN tumor suppression. Cell 133 (2008), 403–414.
29. Abmayr, S.M., Yao, T., Parmely, T.,et al., Preparation of nuclear and cytoplasmic extracts from mammalian cells. Curr. Protoc. Mol. Biol. 12 (2006), 1.1–1.10.
30. Lowry, O.H., Rosebrough, N.J., Farr, A.L.,et al., Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951), 265–275.
31. Zundel, W., Schindler, C., Haas-Kogan, D.,et al., Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 14 (2000), 391–396.
32. Depping, R., Steinhoff, A., Schindler, S.G.,et al., Nuclear translocation of hypoxia-inducible factors (HIFs): involvement of the classical importin alpha/beta pathway. Biochim. Biophys. Acta 1783 (2008), 394–404.
33. Pistollato, F., Rampazzo, E., Persano, L.,et al., Interaction of hypoxia-inducible factor-1α and Notch signaling regulates medulloblastoma precursor proliferation and fate. Stem Cells 28 (2010), 1918–1929.
34. Sun, C., Bernards, R., Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. Trends Biochem. Sci. 39 (2014), 465–474.
35. Hartman, Z.C., Yang, X.Y., Glass, O.,et al., HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis. Cancer Res. 71 (2011), 4380–4391.
36. Li, G., Zhao, L., Li, W.,et al., Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression. Oncotarget 5 (2014), 8317–8329.
37. Sadeghiirizi, A., Yazdanparast, R., Aghazadeh, S., Combating trastuzumab resistance by targeting thioredoxin-1/PTEN interaction. Tumor Biol. 37 (2016), 6737–6747.
38. Iliopoulos, D., Jaeger, S.A., Hirsch, H.A.,et al., STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol. Cell 39 (2010), 493–506.
39. Ye, X., Bai, W., Zhu, H.,et al., MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN. BMB Rep. 47 (2014), 268–273.
40. Whelan, K.A., Schwab, L.P., Karakashev, S.V.,et al., The oncogene HER2/neu (ERBB2) requires the hypoxia-inducible factor HIF-1 for mammary tumor growth and anoikis resistance. J. Biol. Chem. 288 (2013), 15865–15877.
41. Karakashev, S.V., Reginato, M.J., Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2. Oncotarget 6 (2015), 1967–1980.
42. Jung, J.E., Kim, H.S., Lee, C.S.,et al., STAT3 inhibits the degradation of HIF-1alpha by pVHL-mediated ubiquitination. Exp. Mol. Med. 40 (2008), 479–485.
43. Liu, Y., Nie, H., Zhang, K.,et al., A feedback regulatory loop between HIF-1α and miR-21 in response to hypoxia in cardiomyocytes. FEBS Lett. 588 (2014), 3137–3146.
44. Seok, J.K., Lee, S.H., Kim, M.J.,et al., MicroRNA-382 induced by HIF-1α is an angiogenic miR targeting the tumor suppressor phosphatase and tensin homolog. Nucleic Acids Res. 42 (2014), 8062–8072.
45. Wang, R., Zhang, Y.W., Zhang, X.,et al., Transcriptional regulation of APH-1A and increased gamma-secretase cleavage of APP and Notch by HIF-1 and hypoxia. FASEB J. 20 (2006), 1275–1277.
46. Lee, J.H., Suk, J., Park, J.,et al., Notch signal activates hypoxia pathway through HES1-dependent SRC/signal transducers and activators of transcription 3 pathway. Mol. Cancer Res. 7 (2009), 1663–16671.
47. Sajadimajd, S., Yazdanparast, R., Differential behaviors of trastuzumab-sensitive and -resistant SKBR3 cells treated with menadione reveal the involvement of Notch1/Akt/FOXO1 signaling elements. Mol. Cell. Biochem. 408 (2015), 89–102.